These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34884316)

  • 1. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future.
    Szeto CH; Shalata W; Yakobson A; Agbarya A
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
    Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
    Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
    Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
    Xu Z; Zou Z; Hao X; Xing P; Li J
    Cancer Innov; 2023 Feb; 2(1):65-78. PubMed ID: 38090369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
    Peng Y; Li Z; Fu Y; Pan Y; Zeng Y; Liu J; Xiao C; Zhang Y; Su Y; Li G; Wu F
    Front Oncol; 2023; 13():1011810. PubMed ID: 36761954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
    Shukla N; Hanna N
    Lung Cancer (Auckl); 2021; 12():51-60. PubMed ID: 34234606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
    Viscardi G; Vitiello F; Servetto A; Gristina V; Pizzutilo EG; Canciello MA; Medusa PM; Salomone F; Di Guida G; Mollica M; Aronne L; Scaramuzzi R; Napolitano F; Battiloro C; Caputo F; Gilli M; Totaro G; Curcio C; Rocco D; Montesarchio V
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
    Huynh C; Walsh LA; Spicer JD
    Transl Lung Cancer Res; 2021 Jan; 10(1):563-580. PubMed ID: 33569337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for early-stage non-small cell lung cancer: A system review.
    Gao J; Zhang C; Wei Z; Ye X
    J Cancer Res Ther; 2023 Aug; 19(4):849-865. PubMed ID: 37675709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety.
    Shao L; Lou G
    J Thorac Dis; 2022 Sep; 14(9):3565-3574. PubMed ID: 36245597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
    Lochrin SE; Forde PM
    Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
    Conroy MR; Dennehy C; Forde PM
    Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.